The main research of this laboratory concerns molecular mechanisms of viral pathogenesis.
Fifteen percent of human cancers are associated with or caused by viruses. We are investigating if a virus similar to the mouse mammary tumor virus (MMTV) is involved in human breast cancer pathogenesis. We have found viral sequences similar to MMTV in 38% of the human breast cancers tested. They were expressed as RNA and proteins. A complete proviral structure has been detected with the characteristics of a replicative competent virus.
Recently, we isolated and characterized a beta retrovirus from primary cultures of human breast cancer cells. The retrovirus is able to infect epithelial and lymphocytic human cells. Its potential for malignant transformation is being investigated. Epidemiological studies on breast cancer and retroviral incidence are also carried out by analyzing samples from different geographical locations. The transcriptional profile of breast cancer cells carrying the virus was also investigated. Together, these studies will help to determine if a retrovirus is involved in human breast cancer pathogenesis.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Pogo has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Pogo has not yet completed reporting of Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.